

DRAWINGS




FIG. 1

CR20214, 10 nM to 1000 nM, 6 h




FIG. 2




FIG. 3A




FIG. 3B

Duration of action: 6h




FIG. 4A

Duration of action: 24h




FIG. 4B




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 10A Change in tumor volume in human prostate cancer 22Rv-1 tumor-bearing mouse model receiving CR202 series of compounds




FIG. 10B Change in body weight in human prostate cancer 22Rv-1 tumor-bearing mouse model receiving CR202 series of compounds